

Yuan Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5066957/publications.pdf>

Version: 2024-02-01

27
papers

2,031
citations

430874

18
h-index

501196

28
g-index

28
all docs

28
docs citations

28
times ranked

3961
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. <i>Nature Cell Biology</i> , 2015, 17, 183-194.	10.3	895
2	Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. <i>Nature Cell Biology</i> , 2018, 20, 597-609.	10.3	306
3	SUMO-mediated regulation of NLRP3 modulates inflammasome activity. <i>Nature Communications</i> , 2018, 9, 3001.	12.8	134
4	Role of an N-Terminal Site of Ubc9 in SUMO-1, -2, and -3 Binding and Conjugation. <i>Biochemistry</i> , 2003, 42, 9959-9969.	2.5	89
5	Role of SUMO activating enzyme in cancer stem cell maintenance and self-renewal. <i>Nature Communications</i> , 2016, 7, 12326.	12.8	78
6	Hydroxamic Acid and Benzoic Acid-Based STAT3 Inhibitors Suppress Human Glioma and Breast Cancer Phenotypes <i>In Vitro</i> and <i>In Vivo</i> . <i>Cancer Research</i> , 2016, 76, 652-663.	0.9	66
7	Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme. <i>Nature Communications</i> , 2018, 9, 5145.	12.8	46
8	Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. <i>Nature Communications</i> , 2017, 8, 2099.	12.8	45
9	Identification and Characterization of a New Chemotype of Noncovalent SENP Inhibitors. <i>ACS Chemical Biology</i> , 2013, 8, 1435-1441.	3.4	38
10	Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme. <i>Cell Chemical Biology</i> , 2019, 26, 278-288.e6.	5.2	36
11	Impaired p32 Regulation Caused by the Lymphoma-Prone RECQ4 Mutation Drives Mitochondrial Dysfunction. <i>Cell Reports</i> , 2014, 7, 848-858.	6.4	28
12	The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA. <i>Clinical Cancer Research</i> , 2018, 24, 6053-6065.	7.0	27
13	Allosteric Communication across STAT3 Domains Associated with STAT3 Function and Disease-Causing Mutation. <i>Journal of Molecular Biology</i> , 2016, 428, 579-589.	4.2	24
14	Streptonigrin Inhibits SENP1 and Reduces the Protein Level of Hypoxia-Inducible Factor 1 α (HIF1 α) in Cells. <i>Biochemistry</i> , 2018, 57, 1807-1813.	2.5	23
15	Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin β -2 Expression, and Induce Antitumor Effects against Human Glioma. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7734-7748.	6.4	22
16	Sumoylation of ROR γ t regulates TH17 differentiation and thymocyte development. <i>Nature Communications</i> , 2018, 9, 4870.	12.8	22
17	Domain alternation and active site remodeling are conserved structural features of ubiquitin E1. <i>Journal of Biological Chemistry</i> , 2017, 292, 12089-12099.	3.4	22
18	HIF-1-alpha links mitochondrial perturbation to the dynamic acquisition of breast cancer tumorigenicity. <i>Oncotarget</i> , 2016, 7, 34052-34069.	1.8	21

#	ARTICLE	IF	CITATIONS
19	Multi-Kinase Inhibitor with Anti-p38 ^β Activity in Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2377-2387.	0.7	16
20	Regulation of miR-34b/c-targeted gene expression program by SUMOylation. <i>Nucleic Acids Research</i> , 2018, 46, 7108-7123.	14.5	16
21	Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain Inhibitor Pyrvinium. <i>ACS Omega</i> , 2019, 4, 2472-2481.	3.5	16
22	Mechanism of E1-E2 Interaction for the Inhibition of Ubl Adenylation. <i>Journal of Biological Chemistry</i> , 2010, 285, 33457-33462.	3.4	15
23	Conformational flexibility and changes underlying activation of the SUMO-specific protease SENP1 by remote substrate binding. <i>Nature Communications</i> , 2014, 5, 4968.	12.8	15
24	A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy. <i>Oncotarget</i> , 2017, 8, 79750-79760.	1.8	12
25	MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. <i>Anticancer Research</i> , 2017, 37, 2831-2838.	1.1	11
26	Design of High-Throughput Screening Assays and Identification of a SUMO1-Specific Small Molecule Chemotype Targeting the SUMO-Interacting Motif-Binding Surface. <i>ACS Combinatorial Science</i> , 2015, 17, 239-246.	3.8	5
27	Observation of an E2 (Ubc9)-homodimer by crystallography. <i>Data in Brief</i> , 2016, 7, 195-200.	1.0	2